Dawes J, Bara L, Billaud E, Samama M
Haemostasis. 1986;16(2):116-22. doi: 10.1159/000215281.
The pharmacokinetics of unfractionated heparin and the low-molecular-weight (LMW) heparin PK 10169 after intravenous and subcutaneous injection were compared by crossover study in 8 healthy volunteers. The heparin concentrations in plasma were measured by a competitive binding assay, and anti-IIa and anti-Xa activities were also assayed. Unfractionated heparin was cleared after intravenous administration with a half-life of 35 min irrespective of assay method. However, the concentration of PK 10169 declined with the longer half-life of 60 min, and its anti-IIa and anti-Xa activities had half-lives of 40 and 275 min, respectively. Some of this anti-Xa activity may be mediated by a compound released by PK 10169 rather than by the LMW heparin itself. The bioavailability of PK 10169 was 3-fold greater than that of unfractionated heparin, due to more effective absorption after subcutaneous administration.
通过交叉研究,在8名健康志愿者中比较了静脉注射和皮下注射普通肝素与低分子量肝素PK 10169后的药代动力学。采用竞争性结合试验测定血浆中的肝素浓度,并检测抗IIa和抗Xa活性。静脉给药后,普通肝素的清除半衰期为35分钟,与检测方法无关。然而,PK 10169的浓度下降,半衰期更长,为60分钟,其抗IIa和抗Xa活性的半衰期分别为40分钟和275分钟。这种抗Xa活性的一部分可能由PK 10169释放的一种化合物介导,而非低分子量肝素本身。由于皮下给药后吸收更有效,PK 10169的生物利用度比普通肝素高3倍。